Next Article in Journal
Oromucosal Administration of Interferon to Humans
Next Article in Special Issue
Oxytocin and Major Depressive Disorder: Experimental and Clinical Evidence for Links to Aetiology and Possible Treatment
Previous Article in Journal
Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE)
Previous Article in Special Issue
The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments
Pharmaceuticals 2010, 3(1), 273-299; doi:10.3390/ph3010273

Nitric Oxide Synthase Inhibitors as Antidepressants

1,*  and 2
Received: 10 November 2009 / Revised: 7 January 2010 / Accepted: 19 January 2010 / Published: 20 January 2010
(This article belongs to the Special Issue Antidepressants)
View Full-Text   |   Download PDF [251 KB, uploaded 20 January 2010]   |   Browse Figure
Abstract: Affective and anxiety disorders are widely distributed disorders with severe social and economic effects. Evidence is emphatic that effective treatment helps to restore function and quality of life. Due to the action of most modern antidepressant drugs, serotonergic mechanisms have traditionally been suggested to play major roles in the pathophysiology of mood and stress-related disorders. However, a few clinical and several pre-clinical studies, strongly suggest involvement of the nitric oxide (NO) signaling pathway in these disorders. Moreover, several of the conventional neurotransmitters, including serotonin, glutamate and GABA, are intimately regulated by NO, and distinct classes of antidepressants have been found to modulate the hippocampal NO level in vivo. The NO system is therefore a potential target for antidepressant and anxiolytic drug action in acute therapy as well as in prophylaxis. This paper reviews the effect of drugs modulating NO synthesis in anxiety and depression.
Keywords: nitric oxide; antidepressants; psychiatry; depression; anxiety nitric oxide; antidepressants; psychiatry; depression; anxiety
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Wegener, G.; Volke, V. Nitric Oxide Synthase Inhibitors as Antidepressants. Pharmaceuticals 2010, 3, 273-299.

AMA Style

Wegener G, Volke V. Nitric Oxide Synthase Inhibitors as Antidepressants. Pharmaceuticals. 2010; 3(1):273-299.

Chicago/Turabian Style

Wegener, Gregers; Volke, Vallo. 2010. "Nitric Oxide Synthase Inhibitors as Antidepressants." Pharmaceuticals 3, no. 1: 273-299.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert